The Resurgence of the Vacuum Erection Device (VED) for Treatment of Erectile Dysfunction

Abstract

Introduction Vacuum erection devices (VEDs) have been approved in the United States since 1982 and offer a viable alternative to oral phosphodiesterase type 5 inhibitors (PDE5i), injections and transurethral suppositories. Studies have demonstrated efficacy in erectile dysfunction (ED) associated with a variety of conditions. More recently, this modality has been evaluated in initial phosphodiesterase inhibitor nonresponders as well as for post-prostatectomy penile rehabilitation. Aim This article provides a detailed overview of the history of VEDs, a review of the literature, and a concise description of their new applications in modern urological practice. Methods A retrospective review of publications relevant to the field of VEDs. Main Outcome Measures Review of the historical milestones, evolution, and modern utilization of VEDs in modern urological protocols. Results Studies have demonstrated efficacy in ED associated with a variety of conditions. Early penile rehabilitation after surgery for prostate cancer with the VED appears to improve erectile function and penile length. Adverse events are transient and not serious. Conclusions The VED has continued to show efficacy for treatment of ED due to various etiologies and should be considered an attractive second-line therapy. In select cases such post-prostatectomy penile rehabilitation, as well as in men who cannot use a PDE5i, the vacuum device should be considered first-line treatment.

Psychosocial perspectives on sexual recovery after prostate cancer treatment

“…59,70 One small study (n = 20) showed evidence that the use of a VED improves penile oxygen saturation. 71 Two randomized controlled trials 72,73 suggest VEDs as a viable penile rehabilitation strategy.…”

Sexual Dysfunction in Cancer Patients and Survivors #293

“…Oral PDE-5 inhibitors (such as sildenafil), vacuum erection devices, penile prosthesis, and intracavernous injections (such as alprostadil) have been shown to be effective in iatrogenic erectile dysfunction from cancer therapy. [15][16][17][18][19] Some experts advise that patients should avoid sexual intercourse if the malignancy is present in the genital tract, if the patient is still healing from genital surgery, or if neutropenia (ANC <1000) and/or thrombocytopenia (platelets <50,000) is present, to minimize the bleeding and infection risk. Patients commonly ask if chemotherapy can cause adverse effects in partners with whom they are sexually intimate.…”

Post-prostatectomy erectile dysfunction: contemporary approaches from a US perspective

“…Geddings D Osbon, Sr, is regarded as the individual who popularized the vacuum erection device in the 1960s, and the US Food and Drug Administration approved the first marketed vacuum erection device in 1982 30. The vacuum erection device creates an artificial erection by forming a vacuum via suction of air to draw blood into the penis.…”